CY1123908T1 - Δισκιο με εντερικη επικαληψη - Google Patents

Δισκιο με εντερικη επικαληψη

Info

Publication number
CY1123908T1
CY1123908T1 CY20201101162T CY201101162T CY1123908T1 CY 1123908 T1 CY1123908 T1 CY 1123908T1 CY 20201101162 T CY20201101162 T CY 20201101162T CY 201101162 T CY201101162 T CY 201101162T CY 1123908 T1 CY1123908 T1 CY 1123908T1
Authority
CY
Cyprus
Prior art keywords
coating layer
enteric
coated tablet
polymer
amount
Prior art date
Application number
CY20201101162T
Other languages
English (en)
Inventor
Akio RYU
Miyako OSADA
Original Assignee
Zeria Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51391349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123908(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zeria Pharmaceutical Co., Ltd. filed Critical Zeria Pharmaceutical Co., Ltd.
Publication of CY1123908T1 publication Critical patent/CY1123908T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Παρέχεται ένα δισκίο με εντερική επικάλυψη που περιέχει μια μεγάλη ποσότητα φαρμακευτικού συστατικού και έχει επαρκή αντοχή στην κρούση, χωρίς να σχηματίζει ένα παχύ στρώμα εντερικής επίστρωσης. Το δισκίο με εντερική επικάλυψη περιέχει (Α) ένα δισκίο πυρήνα που περιέχει ένα φαρμακευτικό συστατικό και έχει βάρος 1.000 mg ή περισσότερο. (Β) ένα στρώμα επικάλυψης που περιέχει ένα υδατοδιαλυτό πολυμερές που εφαρμόζεται στην επιφάνεια του πυρήνα του δισκίου και (Γ) ένα στρώμα εντερικής επικάλυψης που διαλύεται σε pΗ 7 ή υψηλότερο το οποίο εφαρμόζεται στην επιφάνεια του στρώματος επικάλυψης που περιέχει ένα υδατοδιαλυτό πολυμερές, όπου το άθροισμα της ποσότητας πολυμερούς του στρώματος επικάλυψης (Β) και της ποσότητας πολυμερούς του στρώματος επικάλυψης (Γ) είναι 10 έως 18 mg / cm2, η ποσότητα πολυμερούς της στρώσης επικάλυψης (Β) είναι 6 έως 12 mg/cm2 και η ποσότητα πολυμερούς της στρώσης επικάλυψης (Γ) είναι 3 έως 6 mg / cm.2.
CY20201101162T 2013-02-22 2020-12-08 Δισκιο με εντερικη επικαληψη CY1123908T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013032759 2013-02-22
PCT/JP2014/054104 WO2014129568A1 (ja) 2013-02-22 2014-02-21 腸溶錠

Publications (1)

Publication Number Publication Date
CY1123908T1 true CY1123908T1 (el) 2022-03-24

Family

ID=51391349

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101162T CY1123908T1 (el) 2013-02-22 2020-12-08 Δισκιο με εντερικη επικαληψη

Country Status (25)

Country Link
US (4) US20150374632A1 (el)
EP (1) EP2959892B1 (el)
JP (1) JP6237760B2 (el)
KR (1) KR102167265B1 (el)
CN (1) CN105025888B (el)
AU (1) AU2014219726B2 (el)
BR (1) BR112015020237B1 (el)
CA (1) CA2901166C (el)
CY (1) CY1123908T1 (el)
DK (1) DK2959892T3 (el)
ES (1) ES2821766T3 (el)
HR (1) HRP20201808T1 (el)
HU (1) HUE052167T2 (el)
IL (1) IL240575B (el)
LT (1) LT2959892T (el)
MX (1) MX369967B (el)
NZ (1) NZ711201A (el)
PT (1) PT2959892T (el)
RS (1) RS61099B1 (el)
RU (1) RU2675844C2 (el)
SG (1) SG11201506653WA (el)
SI (1) SI2959892T1 (el)
TW (1) TWI688411B (el)
WO (1) WO2014129568A1 (el)
ZA (1) ZA201506585B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990578C (en) 2015-06-30 2023-09-26 National University Corporation Okayama University Drug for preventing or treating inflammatory bowel disease
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
CN106511277A (zh) * 2016-11-22 2017-03-22 吉林省博大伟业制药有限公司 一种聚普瑞锌颗粒剂及其制备方法
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
EP3662898A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58109413A (ja) * 1981-12-23 1983-06-29 Eisai Co Ltd 耐衝撃性腸溶錠
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
ITMI991316A1 (it) * 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
EP1453487B2 (en) * 2001-11-23 2021-03-31 Allergan Pharmaceuticals International Limited Pharmaceutical dosage form with multiple coatings
WO2004062577A2 (en) * 2003-01-03 2004-07-29 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
RU2375048C2 (ru) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
MY147202A (en) 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
SI2152250T1 (sl) * 2007-05-07 2020-06-30 Evonik Operations Gmbh Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila
WO2009047802A2 (en) * 2007-10-10 2009-04-16 Lupin Limited Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US8329208B2 (en) * 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
CN101732280B (zh) * 2009-10-23 2012-04-18 天津力生制药股份有限公司 一种结肠定位释药的口服制剂
EP2425826A1 (en) * 2010-09-01 2012-03-07 Disphar International B.V. Mesalazine tablet having improved dissolution
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
JOP20200144A1 (ar) * 2012-04-30 2017-06-16 Tillotts Pharma Ag تركيبة عقار ذو إطلاق متأخر

Also Published As

Publication number Publication date
IL240575A0 (en) 2015-09-24
RU2675844C2 (ru) 2018-12-25
US20190015345A1 (en) 2019-01-17
IL240575B (en) 2020-07-30
US20210093577A1 (en) 2021-04-01
ES2821766T3 (es) 2021-04-27
ZA201506585B (en) 2017-03-29
RU2015140119A3 (el) 2018-03-06
KR20150118160A (ko) 2015-10-21
SI2959892T1 (sl) 2020-12-31
AU2014219726B2 (en) 2018-03-15
CA2901166C (en) 2020-03-24
HRP20201808T1 (hr) 2021-01-08
EP2959892A1 (en) 2015-12-30
JPWO2014129568A1 (ja) 2017-02-02
BR112015020237A2 (pt) 2017-07-18
DK2959892T3 (da) 2020-09-21
KR102167265B1 (ko) 2020-10-19
CN105025888B (zh) 2018-10-12
CA2901166A1 (en) 2014-08-28
TW201501731A (zh) 2015-01-16
PT2959892T (pt) 2020-12-15
EP2959892A4 (en) 2016-10-05
HUE052167T2 (hu) 2021-04-28
BR112015020237B1 (pt) 2022-09-13
RU2015140119A (ru) 2017-03-30
US20150374632A1 (en) 2015-12-31
WO2014129568A1 (ja) 2014-08-28
JP6237760B2 (ja) 2017-11-29
LT2959892T (lt) 2020-12-10
TWI688411B (zh) 2020-03-21
AU2014219726A1 (en) 2015-09-10
MX369967B (es) 2019-11-27
SG11201506653WA (en) 2015-09-29
MX2015010871A (es) 2015-12-01
NZ711201A (en) 2019-10-25
RS61099B1 (sr) 2020-12-31
CN105025888A (zh) 2015-11-04
US20230372250A1 (en) 2023-11-23
EP2959892B1 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
CY1123908T1 (el) Δισκιο με εντερικη επικαληψη
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA45690A (fr) Anticorps anti-tgfb, méthodes et utilisations
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
DK3198742T3 (da) Netværksknude, brugerindretning og fremgangsmåder deri for at gøre det muligt for brugerindretningen at bestemme en forkoderkodebog
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
DK3740504T5 (da) CD70 kombinationsterapi
MA43419A (fr) Bloc copolymères formant un couche polyélectrolytique, compositions et leurs utilisations
MA49749A (fr) Anticorps anti-cd137
MA43567A (fr) Anticorps pacap et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
CL2016001211A1 (es) Aparato y método de registro de hoyo.
BR112017013111A2 (pt) métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo
MA49133A (fr) Anticorps agonistes anti-btla et leurs utilisations
MA46562A (fr) Anticorps anti-chikv et leurs utilisations
DK3614371T3 (da) Modulært klaverklaviatur
CY1120788T1 (el) Μορφοποιηση πολυτροπικης εκλυσης δοξυλαμινης και πυριδοξινης ή/και μεταβολιτων ή αλατων αυτων
DK3638313T5 (da) Ikke-kovalent samlet biomatrixlag
IT201700094491A1 (it) Reattore.
CL2020000451S1 (es) Cápsula.
CL2018003014S1 (es) Cápsula.
CL2018003015S1 (es) Cápsula.
DK3514101T3 (da) Kran